Clinical Trials Sponsored by AstraZeneca

Total 4282 results

AstraZeneca

Completed

Tolerability/Safety of Intranasal AZD8848 in Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out of Season (SAD)

Healthy | Allergic Rhinitis

Sweden
AstraZeneca

Terminated

Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients

Acute Myeloid Leukemia

United States, Canada
AstraZeneca

Completed

Prevalence and Risk Factors in Unipolar Depression Patients Without Remission After One Antidepressant Trial (PANTHER)

Non-psychotic Unipolar Major Depression

Argentina
AstraZeneca

Completed

Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers

Solid Tumours

United Kingdom
AstraZeneca

Completed

Study to Investigate Safety, Tolerability and Effect of Multiple Dosing With AZD 4721 and/or With AZD 5069

Chronic Obstructive Pulmonary Disease (COPD).

United Kingdom
AstraZeneca

Terminated

Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM

Type 2 Diabetes Mellitus

United States
AstraZeneca

Completed

Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC)

Type 2 Diabetes Mellitus
AstraZeneca

Completed

Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)

Diabetes Mellitus

United States
AstraZeneca

Completed

Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)

Type 2 Diabetes Mellitus

United States
AstraZeneca

Completed

Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR

Diabetes Mellitus

United States
AstraZeneca

Completed

Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants

Type 2 Diabetes Mellitus

United States
AstraZeneca

Completed

Bioequivalence Study of Fixed-dose Combinations and Coadministered Individual Tablets of Saxagliptin/Metformin-Brazil

Type 2 Diabetes Mellitus

Brazil
AstraZeneca

Completed

Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants

Type 2 Diabetes Mellitus

United States
AstraZeneca

Completed

A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Type 2 Diabetes

United States
AstraZeneca

Completed

A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas

Diabetes

Korea, Republic of, Mexico, Taiwan, United States, Argentina, Brazil, Puerto Rico, South Africa, Hong Kong, Israel, Singapore, Peru, Philippines
AstraZeneca

Completed

The Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects

Hypertriglyceridemia

United States
AstraZeneca

Completed

Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals

Hypertriglyceridemia

United States
AstraZeneca

Completed

A Phase IIa Study Assessing the Effects of AZD1236 on Biomarkers in Chronic Obstructive Pulmonary Disease (COPD) Patients (BICO)

Chronic Obstructive Pulmonary Disease

Denmark, Finland, Norway, Netherlands
AstraZeneca

Completed

Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects

Obesity | Overweight

United States
AstraZeneca

Completed

Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin

Obesity

United States
AstraZeneca

Completed

A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
AstraZeneca

Completed

An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia

Familial Hypercholesterolaemia

United States, Netherlands, Norway, Canada, Belgium
AstraZeneca

Completed

Acid-suppressing Drugs Pregnancy Asthma Offspring Study

Asthma in Offspring

Spain
AstraZeneca

Completed

A First Time in Man Study to Asses the Safety and Tolerability of AZD7624 in Healthy Subjects

Chronic Obstructive Pulmonary Disease (COPD)

United Kingdom
AstraZeneca

Completed

A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects

Obesity | Overweight

United States
AstraZeneca

Completed

AZD5423 Multiple Ascending Dose Study

Healthy

United Kingdom
AstraZeneca

Completed

Retrospective Observational Study DIANA Study (DIANA)

Major Depressive Episode

Russian Federation
AstraZeneca

Completed

Open-label Study to Assess the Pharmacokinetics of NKTR-118 in Patients With Impaired Hepatic Function

Hepatic; Functional Disturbance

United States
AstraZeneca

Completed

Study in Healthy Volunteers to Investigate the Effects of Quinidine on the Pharmacokinetics of NKTR-118

Drug Induced Constipation

United States
AstraZeneca

Completed

Study in Healthy Volunteers to Investigate the Effects of Rifampin on the Pharmacokinetics of NKTR-118

Drug Induced Constipation

United States
AstraZeneca

Completed

A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects

Amount of NKTR-118 in Blood | Variation in the Heart's Electrical Cycle

United States
AstraZeneca

Completed

Assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects

Healthy

United States
AstraZeneca

Completed

Absorption, Distribution, Metabolism and Excretion (ADME) Study With Single Oral Administration of [14C] NKTR-118

Healthy Volunteers

United Kingdom
AstraZeneca

Completed

Open Label, Healthy Volunteers, Bioequivalence Study With Naloxegol

Opioid Induced Constipation

United Kingdom
AstraZeneca

Withdrawn

Adenosine-induced Myocardial Blood Flow in Peripheral Artery Disease Patients (PAD)

Intermittent Claudication | Peripheral Artery Disease | Vascular Disease | Arterial Occlusion Disease | Ankle Brachial Index (0.9 or Less)
AstraZeneca

Completed

Study in Healthy Volunteers to Investigate the Effects of Ketoconazole on the Pharmacokinetics of NKTR-118

Healthy Volunteers | Bioavailability | Drug- Drug Interactions

United States
AstraZeneca

Completed

Faslodex Post Marketing Surveillance

Breast Cancer

Korea, Republic of
AstraZeneca

Completed

A Pharmacodynamic Study With Ticagrelor in African American Patients

Stable Coronary Artery Disease

United States
AstraZeneca

Completed

A Study to Assess Safety,and Tolerability of 2 Doses of AZD9773 (CytoFab™) in Japanese With Severe Sepsis/Septic Shock

Septic Shock | Severe Sepsis

Japan
AstraZeneca

Completed

A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab™) With Placebo in Adult Patients With Severe Sepsis and/or Septic Shock

Septic Shock | Severe Sepsis

Czech Republic, France, Spain, Finland, Canada, Australia, Belgium
AstraZeneca

Terminated

Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer

Metastatic, Gastric or Gastro-oesophageal Junction, Cancer

Korea, Republic of, Spain, Taiwan, Germany, Japan
AstraZeneca

Completed

Evaluation of Succinate Metoprolol on Heart Rate in the Stable Angina Patients

Angina Pectoris

China
AstraZeneca

Completed

An Epidemiological Registry Study to Evaluate Clinical Practice Treatment in Patients With Bipolar Disorder (REED)

Bipolar Disorder
AstraZeneca

Terminated

Pharmacokinetic Interaction Between AZD3480 and Donepezil

Alzheimer's Disease

United Kingdom
AstraZeneca

Completed

OPtimal Type 2 dIabetes Management Including Benchmarking and Standard Treatment in CEEMEA (OPTIMISE)

Diabetes Mellitus, Non-Insulin-Dependent

Bulgaria, Romania
AstraZeneca

Completed

AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen

Non-small Cell Lung Cancer

United States, Bulgaria, Romania
AstraZeneca

Completed

Phase II Efficacy Study of AZD6244 in Colorectal Cancer

Metastatic Colorectal Cancer

Brazil
AstraZeneca

Completed

Randomised Study to Compare the Efficacy of AZD6244 vs TMZ

Melanoma

United States, Australia, Brazil, United Kingdom, Argentina, Austria, Canada, Denmark, France, Switzerland
AstraZeneca

Completed

AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy

Pancreatic Cancer

United States, Bulgaria, Hungary, Romania, Australia
AstraZeneca

Terminated

Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer (MINT)

Neoplasms | Breast Cancer | Breast Neoplasms

Brazil, Czech Republic, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, South Africa, United Kingdom, Philippines, Ukraine, Finland, Canada, Taiwan, India, Thailand, United States, Japan

3

Subscribe